Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.5800+0.1100 (+4.45%)
At close: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4700
Open2.4400
Bid2.5700 x 1100
Ask2.5800 x 1200
Day's Range2.3700 - 2.7100
52 Week Range2.2400 - 11.5200
Volume567,747
Avg. Volume846,343
Market Cap135.196M
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-2.2410
Earnings DateMar 16, 2022 - Mar 21, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.81
  • GuruFocus.com

    Henry James International Management Inc. ...

    Investment company Henry James International Management Inc. (Current Portfolio) buys Alibaba Group Holding, iShares MSCI Emerging Markets ETF, Materialise NV, EPAM Systems Inc, Endava PLC, sells Core Laboratories NV, Betterware de Mexico SAB de CV, Gazprom PJSC, Piedmont Lithium Inc, Cellectis SA during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Henry James International Management Inc..

  • Benzinga

    RedHill Biopharma's Oral COVID-19 Treatment Improves Median Time To Viral RNA Clearance

    RedHill Biopharma Ltd (NASDAQ: RDHL) announced new data from a prespecified analysis of all oral opaganib's Phase 2/3 study patients in COVID-19 patients. The data demonstrated that opaganib improved the median time to viral RNA clearance by at least four days. Treatment with opaganib resulted in viral RNA clearance in a median of 10 days, while the median for clearance in the placebo arm was not reached by the end of 14-days of treatment for placebo. Related: Why Did RedHill Biopharma Shares Ju

  • PR Newswire

    RedHill Biopharma's Oral Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study in Severely Ill Hospitalized COVID-19 Patients

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new data from a prespecified analysis of all oral opaganib's[1] Phase 2/3 study patients with positive PCR at screening, demonstrating that opaganib improved the median time to viral RNA clearance by at least 4 days. Treatment with opaganib resulted in viral RNA clearance in a median of 10 days while the median for clearance in the placebo arm was not reached by the end of 1

Advertisement
Advertisement